News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

04.01.2012 | 2012-01-04_Press_release_Epigenomics_initiation_PMA_filing

Berlin, Germany, and Seattle, WA, U.S.A. – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, is pleased to announce that it has submitted the first module of its premarket approval (PMA) submission to the US Food and Drug Administration (FDA) on December 30, 2011.

On December 30, 2011 Epigenomics has initiated the process of gaining US regulatory approval of its colorectal cancer (CRC) screening test Epi proColon® by submitting the first module of its modular PMA approval submission to the FDA. The first module of the submission includes all required documentation on the manufacturing and quality controls section in relation to the product. Further modules are scheduled to be submitted throughout the first and second quarters of 2012 and the final module, including all clinical data is scheduled for submission in the second half of 2012. Under the FDA’s modular PMA submission protocol, in its guidance document “Guidance for Industry and FDA staff – Premarket Approval Application Modular Review”, the FDA provides for a 90 day review period by the agency for each individual module.

As previously announced, a head-to-head comparative study with the goal of demonstrating non-inferiority of Epi proColon® to fecal immunochemical testing (FIT) will be an integral part of the clinical module. The design of the clinical study has been discussed with the FDA and upon finalizing of the study protocol, it will be initiated in the coming months. The clinical module of the PMA submission will encompass the results of the head-to-head comparative study, previously announced data from a clinical validation study in a cohort of prospectively collected samples and other clinical study results generated during the development of Epi proColon®.

Geert Nygaard, CEO of Epigenomics commented: “We are pleased that we have initiated the regulatory process for our CRC screening test Epi proColon® with the FDA. We intend to initiate the additional head-to-head study of our product against FIT as soon as possible, which would be required to meet our ambitious timeline for the completion of our submission in the second half of 2012.”

– Ends –

Further Information

Contact Epigenomics AG

Antje Zeise
Manager IR | PR
Epigenomics AG
Tel +49 (0) 30 24345 368
ir@epigenomics.com
www.epigenomics.com

About Epigenomics
Epigenomics (www.epigenomics.com) is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for cancer. The Company’s products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics’ lead product, Epi proColon®, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the U.S.A. The Company’s technology and products have been validated through multiple partnerships with leading global diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an international company with operations in Europe and the U.S.A.

Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.